Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Phase 3 TRIUMPH-1 Trial Results (2026 Update) TRIUMPH-1 is the pivotal Phase 3 obesity trial for retatrutide
Lancet 398, 21262128
Tremfya (guselkumab) Disease area(s): Immunology Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $3.67 billion Why it sold so well: J&Js IL-23 inhibitor Tremfya experienced significant sales growth last year with $3.67 billion in total sales, an increase of 16.6% from 2023
When the dose was increased from 1 mg to 2.4 mg per week, PwO without T2D lost on average 15% of their starting weight [18, 19]
Indeed, cortisol activates the rennin/angiotensin/aldosterone system (RAAS), a complex hormonal network influencing blood pressure, fluid and electrolyte balance, and systemic vascular resistance
The compound progressed through Phase 2 trials under multiple sponsors for postoperative ileus and related gastric-motility indications but did not advance to a marketed therapeutic
US$ 22.77
US$ 23.36
US$ 24.98
US$ 23.30
US$ 23.69
US$ 22.76
US$ 29.68
US$ 28.36
US$ 26.64
